Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

In silico pharmacogenetics of warfarin metabolism NATURE BIOTECHNOLOGY Guo, Y. Y., Weller, P., Farrell, E., Cheung, P., Fitch, B., Clark, D., Wu, S. Y., Wang, J. M., Liao, G. C., Zhang, Z. M., Allard, J., Cheng, J., Nguyen, A., Jiang, S., Shafer, S., Usuka, J., Masjedizadeh, M., Peltz, G. 2006; 24 (5): 531-536

Abstract

Pharmacogenetic approaches can be instrumental for predicting individual differences in response to a therapeutic intervention. Here we used a recently developed murine haplotype-based computational method to identify a genetic factor regulating the metabolism of warfarin, a commonly prescribed anticoagulant with a narrow therapeutic index and a large variation in individual dosing. After quantification of warfarin and nine of its metabolites in plasma from 13 inbred mouse strains, we correlated strain-specific differences in 7-hydroxywarfarin accumulation with genetic variation within a chromosomal region encoding cytochrome P450 2C (Cyp2c) enzymes. This computational prediction was experimentally confirmed by showing that the rate-limiting step in biotransformation of warfarin to its 7-hydroxylated metabolite was inhibited by tolbutamide, a Cyp2c isoform-specific substrate, and that this transformation was mediated by expressed recombinant Cyp2c29. We show that genetic variants responsible for interindividual pharmacokinetic differences in drug metabolism can be identified by computational genetic analysis in mice.

View details for DOI 10.1038/nbt1195

View details for Web of Science ID 000237331300027

View details for PubMedID 16680137

View details for PubMedCentralID PMC1459533